You are using an unsupported browser. Please upgrade your browser to a newer version to get the best experience on DrugBank.
Identification
NameCinchocaine
Accession NumberDB00527  (APRD00915)
TypeSmall Molecule
GroupsApproved, Vet Approved
DescriptionA local anesthetic of the amide type now generally used for surface anesthesia. It is one of the most potent and toxic of the long-acting local anesthetics and its parenteral use is restricted to spinal anesthesia. (From Martindale, The Extra Pharmacopoeia, 30th ed, p1006)
Structure
Thumb
Synonyms
2-Butoxy-N-(2-(diethylamino)ethyl)cinchoninamide
2-Butoxy-N-(alpha-diethylaminoethyl)cinchoninamide
2-Butoxy-N-(beta-diethylaminoethyl)cinchoninamide
2-Butoxy-N-[2-(diethylamino)ethyl]-4-quinolinecarboxamide
2-Butoxy-quinoline-4-carboxylic acid (2-diethylamino-ethyl)-amide
2-Butoxyquinoline-4-carboxylic acid diethylaminoethylamide
2-N-Butoxy-N-(2-diethylaminoethyl)cinchoninamide
alpha-Butyloxycinchonic acid-gamma-diethylethylenediamine
alpha-Butyloxycinchoninic acid diethylethylenediamide
CINCHOCAINE
Cinchocainum
Cincocainio
Dibucaine
Dibucaine base
N-(2-(Diethylamino)ethyl)-2-butoxycinchoninamide
External Identifiers Not Available
Approved Prescription ProductsNot Available
Approved Generic Prescription ProductsNot Available
Approved Over the Counter Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Cvs Hemorrhoidal Topical Analgesicointment10 mg/gtopicalCVS Pharmacy, Inc.2014-01-17Not applicableUs
Dibucaineointment1 g/100gtopicalE. Fougera & Co. a division of Fougera Pharmaceuticals Inc.1968-01-01Not applicableUs
Dibucaineointment1 g/100gtopicalPerrigo New York Inc2011-06-20Not applicableUs
Dibucaineointment.28 g/28gtopicalGeritrex Llc2014-01-06Not applicableUs
Dibucainecream10 mg/gtopicalCVS Pharmacy2010-07-16Not applicableUs
Nupercainalointment1 g/100gtopicalDucere Pharma2013-07-01Not applicableUs
Nupercainal Anesthetic Ont 1%ointment1 %rectal; topicalNovartis Consumer Health Canada Inc.1944-12-31Not applicableCanada
Unapproved/Other Products Not Available
International Brands
NameCompany
CincainNot Available
NupercaineNot Available
SovcaineNot Available
Brand mixtures
NameLabellerIngredients
Nupercainal Antiseptic CrmNovartis Consumer Health Canada Inc.
Salts
Name/CASStructureProperties
Cinchocaine hydrochloride
Thumb
  • InChI Key: IVHBBMHQKZBJEU-UHFFFAOYSA-N
  • Monoisotopic Mass: 379.202654926
  • Average Mass: 379.924
DBSALT000639
Dibucaine hydrochloride
ThumbNot applicableDBSALT001401
Categories
UNIIL6JW2TJG99
CAS number85-79-0
WeightAverage: 343.4632
Monoisotopic: 343.225977187
Chemical FormulaC20H29N3O2
InChI KeyInChIKey=PUFQVTATUTYEAL-UHFFFAOYSA-N
InChI
InChI=1S/C20H29N3O2/c1-4-7-14-25-19-15-17(16-10-8-9-11-18(16)22-19)20(24)21-12-13-23(5-2)6-3/h8-11,15H,4-7,12-14H2,1-3H3,(H,21,24)
IUPAC Name
2-butoxy-N-[2-(diethylamino)ethyl]quinoline-4-carboxamide
SMILES
CCCCOC1=NC2=CC=CC=C2C(=C1)C(=O)NCCN(CC)CC
Taxonomy
DescriptionThis compound belongs to the class of organic compounds known as quinoline carboxamides. These are quinolines in which the quinoline ring system is substituted by one or more carboxamide groups.
KingdomOrganic compounds
Super ClassOrganoheterocyclic compounds
ClassQuinolines and derivatives
Sub ClassQuinoline carboxamides
Direct ParentQuinoline carboxamides
Alternative Parents
Substituents
  • Quinoline-4-carboxamide
  • Quinolone
  • Pyridine carboxylic acid or derivatives
  • Alkyl aryl ether
  • Benzenoid
  • Pyridine
  • Heteroaromatic compound
  • Tertiary aliphatic amine
  • Tertiary amine
  • Secondary carboxylic acid amide
  • Carboxamide group
  • Azacycle
  • Ether
  • Carboxylic acid derivative
  • Hydrocarbon derivative
  • Organooxygen compound
  • Organonitrogen compound
  • Carbonyl group
  • Amine
  • Aromatic heteropolycyclic compound
Molecular FrameworkAromatic heteropolycyclic compounds
External Descriptors
Pharmacology
IndicationFor production of local or regional anesthesia by infiltration techniques such as percutaneous injection and intravenous regional anesthesia by peripheral nerve block techniques such as brachial plexus and intercostal and by central neural techniques such as lumbar and caudal epidural blocks.
PharmacodynamicsDibucaine is an amide-type local anesthetic, similar to lidocaine.
Mechanism of actionLocal anesthetics block both the initiation and conduction of nerve impulses by decreasing the neuronal membrane's permeability to sodium ions through sodium channel inhibition. This reversibly stabilizes the membrane and inhibits depolarization, resulting in the failure of a propagated action potential and subsequent conduction blockade.
Related Articles
AbsorptionIn general, ionized forms (salts) of local anesthetics are not readily absorbed through intact skin. However, both nonionized (bases) and ionized forms of local anesthetics are readily absorbed through traumatized or abraded skin into the systemic circulation.
Volume of distributionNot Available
Protein bindingNot Available
Metabolism

Primarily hepatic.

Route of eliminationNot Available
Half lifeNot Available
ClearanceNot Available
ToxicitySubcutaneous LD50 in rat is 27 mg/kg. Symptoms of overdose include convulsions, hypoxia, acidosis, bradycardia, arrhythmias and cardiac arrest.
Affected organisms
  • Humans and other mammals
Pathways
PathwayCategorySMPDB ID
Dibucaine Action PathwayDrug actionSMP00396
SNP Mediated EffectsNot Available
SNP Mediated Adverse Drug ReactionsNot Available
ADMET
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+0.9968
Blood Brain Barrier+0.9876
Caco-2 permeable+0.5187
P-glycoprotein substrateSubstrate0.8702
P-glycoprotein inhibitor IInhibitor0.7536
P-glycoprotein inhibitor IINon-inhibitor0.8862
Renal organic cation transporterNon-inhibitor0.6349
CYP450 2C9 substrateNon-substrate0.8297
CYP450 2D6 substrateNon-substrate0.6415
CYP450 3A4 substrateSubstrate0.6842
CYP450 1A2 substrateInhibitor0.9107
CYP450 2C9 inhibitorNon-inhibitor0.907
CYP450 2D6 inhibitorInhibitor0.8932
CYP450 2C19 inhibitorNon-inhibitor0.9025
CYP450 3A4 inhibitorNon-inhibitor0.8309
CYP450 inhibitory promiscuityLow CYP Inhibitory Promiscuity0.6424
Ames testAMES toxic0.6038
CarcinogenicityNon-carcinogens0.8128
BiodegradationNot ready biodegradable1.0
Rat acute toxicity2.6763 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.8924
hERG inhibition (predictor II)Inhibitor0.6851
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397 )
Pharmacoeconomics
Manufacturers
  • Novartis pharmaceuticals corp
Packagers
Dosage forms
FormRouteStrength
Ointmenttopical10 mg/g
Creamtopical10 mg/g
Ointmenttopical.28 g/28g
Ointmenttopical1 g/100g
Ointmentrectal; topical1 %
Creamtopical
Prices
Unit descriptionCostUnit
Dibucaine hcl powder4.74USD g
Nupercainal 1% ointment0.15USD g
Dibucaine 1% ointment0.12USD g
DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.
PatentsNot Available
Properties
StateSolid
Experimental Properties
PropertyValueSource
melting point99-101 °C (HCl salt)Not Available
water solubility42 mg/L (at 21 °C)BEILSTEIN
logP4.40HANSCH,C ET AL. (1995)
logS-3.7ADME Research, USCD
pKa8.85SANGSTER (1994)
Predicted Properties
PropertyValueSource
Water Solubility0.0389 mg/mLALOGPS
logP3.79ALOGPS
logP3.7ChemAxon
logS-4ALOGPS
pKa (Strongest Acidic)14.57ChemAxon
pKa (Strongest Basic)9.04ChemAxon
Physiological Charge1ChemAxon
Hydrogen Acceptor Count4ChemAxon
Hydrogen Donor Count1ChemAxon
Polar Surface Area54.46 Å2ChemAxon
Rotatable Bond Count10ChemAxon
Refractivity102.12 m3·mol-1ChemAxon
Polarizability40.78 Å3ChemAxon
Number of Rings2ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleYesChemAxon
MDDR-like RuleYesChemAxon
Spectra
Mass Spec (NIST)Not Available
Spectra
Spectrum TypeDescriptionSplash Key
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 10V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 20V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 40V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 10V, NegativeNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 20V, NegativeNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 40V, NegativeNot Available
References
Synthesis Reference

DrugSyn.org

US1825623
General References
  1. Abdel-Ghani NT, Youssef AF, Awady MA: Cinchocaine hydrochloride determination by atomic absorption spectrometry and spectrophotometry. Farmaco. 2005 May;60(5):419-24. [PubMed:15910814 ]
  2. Souto-Padron T, Lima AP, Ribeiro Rde O: Effects of dibucaine on the endocytic/exocytic pathways in Trypanosoma cruzi. Parasitol Res. 2006 Sep;99(4):317-20. Epub 2006 Apr 13. [PubMed:16612626 ]
  3. Nounou MM, El-Khordagui LK, Khalafallah N: Effect of various formulation variables on the encapsulation and stability of dibucaine base in multilamellar vesicles. Acta Pol Pharm. 2005 Sep-Oct;62(5):369-79. [PubMed:16459486 ]
External Links
ATC CodesS02DA04S01HA06N01BB06C05AD04D04AB02
AHFS Codes
  • 84:08.00
PDB EntriesNot Available
FDA labelNot Available
MSDSDownload (73.8 KB)
Interactions
Drug Interactions
Drug
7-NitroindazoleThe risk or severity of adverse effects can be increased when Cinchocaine is combined with 7-Nitroindazole.
AcepromazineThe risk or severity of adverse effects can be increased when Cinchocaine is combined with Acepromazine.
AceprometazineThe risk or severity of adverse effects can be increased when Cinchocaine is combined with Aceprometazine.
adipiplonThe risk or severity of adverse effects can be increased when Cinchocaine is combined with adipiplon.
AgomelatineThe risk or severity of adverse effects can be increased when Cinchocaine is combined with Agomelatine.
AlfaxaloneThe risk or severity of adverse effects can be increased when Cinchocaine is combined with Alfaxalone.
AlfentanilThe risk or severity of adverse effects can be increased when Cinchocaine is combined with Alfentanil.
AlphacetylmethadolThe risk or severity of adverse effects can be increased when Cinchocaine is combined with Alphacetylmethadol.
AlprazolamThe risk or severity of adverse effects can be increased when Alprazolam is combined with Cinchocaine.
AmisulprideThe risk or severity of adverse effects can be increased when Cinchocaine is combined with Amisulpride.
AmitriptylineThe risk or severity of adverse effects can be increased when Cinchocaine is combined with Amitriptyline.
AmobarbitalThe risk or severity of adverse effects can be increased when Cinchocaine is combined with Amobarbital.
AmoxapineThe risk or severity of adverse effects can be increased when Cinchocaine is combined with Amoxapine.
AmperozideThe risk or severity of adverse effects can be increased when Cinchocaine is combined with Amperozide.
AripiprazoleThe risk or severity of adverse effects can be increased when Cinchocaine is combined with Aripiprazole.
ArticaineThe risk or severity of adverse effects can be increased when Cinchocaine is combined with Articaine.
AsenapineThe risk or severity of adverse effects can be increased when Cinchocaine is combined with Asenapine.
AzaperoneThe risk or severity of adverse effects can be increased when Cinchocaine is combined with Azaperone.
AzelastineCinchocaine may increase the central nervous system depressant (CNS depressant) activities of Azelastine.
AzelastineThe risk or severity of adverse effects can be increased when Azelastine is combined with Cinchocaine.
BaclofenThe risk or severity of adverse effects can be increased when Cinchocaine is combined with Baclofen.
BarbitalThe risk or severity of adverse effects can be increased when Cinchocaine is combined with Barbital.
BenzocaineThe risk or severity of adverse effects can be increased when Cinchocaine is combined with Benzocaine.
Benzyl alcoholThe risk or severity of adverse effects can be increased when Cinchocaine is combined with Benzyl alcohol.
BrexpiprazoleThe risk or severity of adverse effects can be increased when Cinchocaine is combined with Brexpiprazole.
BrimonidineBrimonidine may increase the central nervous system depressant (CNS depressant) activities of Cinchocaine.
BrimonidineThe risk or severity of adverse effects can be increased when Cinchocaine is combined with Brimonidine.
BromazepamThe risk or severity of adverse effects can be increased when Cinchocaine is combined with Bromazepam.
BrompheniramineThe risk or severity of adverse effects can be increased when Cinchocaine is combined with Brompheniramine.
BrotizolamThe risk or severity of adverse effects can be increased when Cinchocaine is combined with Brotizolam.
BupivacaineThe risk or severity of adverse effects can be increased when Bupivacaine is combined with Cinchocaine.
BuprenorphineThe risk or severity of adverse effects can be increased when Cinchocaine is combined with Buprenorphine.
BuspironeThe risk or severity of adverse effects can be increased when Buspirone is combined with Cinchocaine.
ButabarbitalThe risk or severity of adverse effects can be increased when Butabarbital is combined with Cinchocaine.
ButacaineThe risk or severity of adverse effects can be increased when Cinchocaine is combined with Butacaine.
ButalbitalThe risk or severity of adverse effects can be increased when Cinchocaine is combined with Butalbital.
ButambenThe risk or severity of adverse effects can be increased when Cinchocaine is combined with Butamben.
ButethalThe risk or severity of adverse effects can be increased when Cinchocaine is combined with Butethal.
ButorphanolThe risk or severity of adverse effects can be increased when Cinchocaine is combined with Butorphanol.
CarbamazepineThe risk or severity of adverse effects can be increased when Cinchocaine is combined with Carbamazepine.
CarbinoxamineThe risk or severity of adverse effects can be increased when Cinchocaine is combined with Carbinoxamine.
CarfentanilThe risk or severity of adverse effects can be increased when Cinchocaine is combined with Carfentanil.
CarisoprodolThe risk or severity of adverse effects can be increased when Cinchocaine is combined with Carisoprodol.
CetirizineThe risk or severity of adverse effects can be increased when Cinchocaine is combined with Cetirizine.
Chloral hydrateThe risk or severity of adverse effects can be increased when Cinchocaine is combined with Chloral hydrate.
ChlordiazepoxideThe risk or severity of adverse effects can be increased when Chlordiazepoxide is combined with Cinchocaine.
ChlormezanoneThe risk or severity of adverse effects can be increased when Cinchocaine is combined with Chlormezanone.
ChloroprocaineThe risk or severity of adverse effects can be increased when Cinchocaine is combined with Chloroprocaine.
ChlorphenamineThe risk or severity of adverse effects can be increased when Cinchocaine is combined with Chlorphenamine.
ChlorpromazineThe risk or severity of adverse effects can be increased when Chlorpromazine is combined with Cinchocaine.
ChlorprothixeneThe risk or severity of adverse effects can be increased when Cinchocaine is combined with Chlorprothixene.
ChlorzoxazoneThe risk or severity of adverse effects can be increased when Cinchocaine is combined with Chlorzoxazone.
CitalopramThe risk or severity of adverse effects can be increased when Cinchocaine is combined with Citalopram.
ClemastineThe risk or severity of adverse effects can be increased when Cinchocaine is combined with Clemastine.
ClidiniumThe risk or severity of adverse effects can be increased when Cinchocaine is combined with Clidinium.
ClobazamThe risk or severity of adverse effects can be increased when Cinchocaine is combined with Clobazam.
clomethiazoleThe risk or severity of adverse effects can be increased when Cinchocaine is combined with clomethiazole.
ClomipramineThe risk or severity of adverse effects can be increased when Cinchocaine is combined with Clomipramine.
ClonazepamThe risk or severity of adverse effects can be increased when Cinchocaine is combined with Clonazepam.
ClonidineThe risk or severity of adverse effects can be increased when Cinchocaine is combined with Clonidine.
ClorazepateThe risk or severity of adverse effects can be increased when Cinchocaine is combined with Clorazepate.
ClozapineThe risk or severity of adverse effects can be increased when Clozapine is combined with Cinchocaine.
CocaineThe risk or severity of adverse effects can be increased when Cinchocaine is combined with Cocaine.
CodeineThe risk or severity of adverse effects can be increased when Codeine is combined with Cinchocaine.
CyclizineThe risk or severity of adverse effects can be increased when Cinchocaine is combined with Cyclizine.
CyclobenzaprineThe risk or severity of adverse effects can be increased when Cinchocaine is combined with Cyclobenzaprine.
CyproheptadineThe risk or severity of adverse effects can be increased when Cinchocaine is combined with Cyproheptadine.
DantroleneThe risk or severity of adverse effects can be increased when Cinchocaine is combined with Dantrolene.
DapiprazoleThe risk or severity of adverse effects can be increased when Dapiprazole is combined with Cinchocaine.
DapoxetineThe risk or severity of adverse effects can be increased when Cinchocaine is combined with Dapoxetine.
deramciclaneThe risk or severity of adverse effects can be increased when Cinchocaine is combined with deramciclane.
DesfluraneThe risk or severity of adverse effects can be increased when Cinchocaine is combined with Desflurane.
DesipramineThe risk or severity of adverse effects can be increased when Cinchocaine is combined with Desipramine.
DesloratadineThe risk or severity of adverse effects can be increased when Cinchocaine is combined with Desloratadine.
DetomidineThe risk or severity of adverse effects can be increased when Cinchocaine is combined with Detomidine.
DexbrompheniramineThe risk or severity of adverse effects can be increased when Cinchocaine is combined with Dexbrompheniramine.
DexmedetomidineThe risk or severity of adverse effects can be increased when Cinchocaine is combined with Dexmedetomidine.
DextromoramideThe risk or severity of adverse effects can be increased when Cinchocaine is combined with Dextromoramide.
DextropropoxypheneThe risk or severity of adverse effects can be increased when Cinchocaine is combined with Dextropropoxyphene.
DezocineThe risk or severity of adverse effects can be increased when Cinchocaine is combined with Dezocine.
DiazepamThe risk or severity of adverse effects can be increased when Cinchocaine is combined with Diazepam.
DifenoxinThe risk or severity of adverse effects can be increased when Cinchocaine is combined with Difenoxin.
DihydrocodeineThe risk or severity of adverse effects can be increased when Cinchocaine is combined with Dihydrocodeine.
DihydroetorphineThe risk or severity of adverse effects can be increased when Cinchocaine is combined with Dihydroetorphine.
DihydromorphineThe risk or severity of adverse effects can be increased when Cinchocaine is combined with Dihydromorphine.
DimenhydrinateThe risk or severity of adverse effects can be increased when Cinchocaine is combined with Dimenhydrinate.
DiphenhydramineThe risk or severity of adverse effects can be increased when Cinchocaine is combined with Diphenhydramine.
DiphenoxylateThe risk or severity of adverse effects can be increased when Cinchocaine is combined with Diphenoxylate.
DoramectinThe risk or severity of adverse effects can be increased when Cinchocaine is combined with Doramectin.
DoxepinThe risk or severity of adverse effects can be increased when Cinchocaine is combined with Doxepin.
DoxylamineDoxylamine may increase the central nervous system depressant (CNS depressant) activities of Cinchocaine.
DoxylamineThe risk or severity of adverse effects can be increased when Cinchocaine is combined with Doxylamine.
DPDPEThe risk or severity of adverse effects can be increased when Cinchocaine is combined with DPDPE.
DronabinolDronabinol may increase the central nervous system depressant (CNS depressant) activities of Cinchocaine.
DroperidolThe risk or severity of adverse effects can be increased when Droperidol is combined with Cinchocaine.
DrotebanolThe risk or severity of adverse effects can be increased when Cinchocaine is combined with Drotebanol.
DyclonineThe risk or severity of adverse effects can be increased when Cinchocaine is combined with Dyclonine.
EcgonineThe risk or severity of adverse effects can be increased when Cinchocaine is combined with Ecgonine.
ECGONINE METHYL ESTERThe risk or severity of adverse effects can be increased when Cinchocaine is combined with ECGONINE METHYL ESTER.
EfavirenzThe risk or severity of adverse effects can be increased when Cinchocaine is combined with Efavirenz.
EnfluraneThe risk or severity of adverse effects can be increased when Enflurane is combined with Cinchocaine.
EntacaponeThe risk or severity of adverse effects can be increased when Cinchocaine is combined with Entacapone.
EscitalopramThe risk or severity of adverse effects can be increased when Cinchocaine is combined with Escitalopram.
EstazolamThe risk or severity of adverse effects can be increased when Cinchocaine is combined with Estazolam.
EszopicloneThe risk or severity of adverse effects can be increased when Eszopiclone is combined with Cinchocaine.
EthanolCinchocaine may increase the central nervous system depressant (CNS depressant) activities of Ethanol.
EthanolThe risk or severity of adverse effects can be increased when Ethanol is combined with Cinchocaine.
EthchlorvynolThe risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Cinchocaine.
EthosuximideThe risk or severity of adverse effects can be increased when Cinchocaine is combined with Ethosuximide.
EthotoinThe risk or severity of adverse effects can be increased when Cinchocaine is combined with Ethotoin.
Ethyl carbamateThe risk or severity of adverse effects can be increased when Cinchocaine is combined with Ethyl carbamate.
Ethyl loflazepateThe risk or severity of adverse effects can be increased when Cinchocaine is combined with Ethyl loflazepate.
EthylmorphineThe risk or severity of adverse effects can be increased when Cinchocaine is combined with Ethylmorphine.
EtidocaineThe risk or severity of adverse effects can be increased when Cinchocaine is combined with Etidocaine.
EtifoxineThe risk or severity of adverse effects can be increased when Cinchocaine is combined with Etifoxine.
EtizolamThe risk or severity of adverse effects can be increased when Cinchocaine is combined with Etizolam.
EtomidateThe risk or severity of adverse effects can be increased when Etomidate is combined with Cinchocaine.
EtoperidoneThe risk or severity of adverse effects can be increased when Cinchocaine is combined with Etoperidone.
EtorphineThe risk or severity of adverse effects can be increased when Cinchocaine is combined with Etorphine.
EzogabineThe risk or severity of adverse effects can be increased when Cinchocaine is combined with Ezogabine.
FelbamateThe risk or severity of adverse effects can be increased when Cinchocaine is combined with Felbamate.
FencamfamineThe risk or severity of adverse effects can be increased when Cinchocaine is combined with Fencamfamine.
FenfluramineThe risk or severity of adverse effects can be increased when Cinchocaine is combined with Fenfluramine.
FentanylThe risk or severity of adverse effects can be increased when Cinchocaine is combined with Fentanyl.
FexofenadineThe risk or severity of adverse effects can be increased when Cinchocaine is combined with Fexofenadine.
FlibanserinThe risk or severity of adverse effects can be increased when Cinchocaine is combined with Flibanserin.
FludiazepamThe risk or severity of adverse effects can be increased when Cinchocaine is combined with Fludiazepam.
FlunarizineThe risk or severity of adverse effects can be increased when Cinchocaine is combined with Flunarizine.
FlunitrazepamThe risk or severity of adverse effects can be increased when Cinchocaine is combined with Flunitrazepam.
FluoxetineThe risk or severity of adverse effects can be increased when Cinchocaine is combined with Fluoxetine.
FlupentixolThe risk or severity of adverse effects can be increased when Cinchocaine is combined with Flupentixol.
FluphenazineThe risk or severity of adverse effects can be increased when Cinchocaine is combined with Fluphenazine.
FlurazepamThe risk or severity of adverse effects can be increased when Cinchocaine is combined with Flurazepam.
FluspirileneThe risk or severity of adverse effects can be increased when Cinchocaine is combined with Fluspirilene.
Fluticasone PropionateThe risk or severity of adverse effects can be increased when Cinchocaine is combined with Fluticasone Propionate.
FluvoxamineThe risk or severity of adverse effects can be increased when Cinchocaine is combined with Fluvoxamine.
FosphenytoinThe risk or severity of adverse effects can be increased when Cinchocaine is combined with Fosphenytoin.
FospropofolThe risk or severity of adverse effects can be increased when Cinchocaine is combined with Fospropofol.
GabapentinThe risk or severity of adverse effects can be increased when Cinchocaine is combined with Gabapentin.
gabapentin enacarbilThe risk or severity of adverse effects can be increased when Cinchocaine is combined with gabapentin enacarbil.
Gamma Hydroxybutyric AcidThe risk or severity of adverse effects can be increased when Cinchocaine is combined with Gamma Hydroxybutyric Acid.
GlutethimideThe risk or severity of adverse effects can be increased when Cinchocaine is combined with Glutethimide.
GuanfacineThe risk or severity of adverse effects can be increased when Cinchocaine is combined with Guanfacine.
HalazepamThe risk or severity of adverse effects can be increased when Cinchocaine is combined with Halazepam.
HaloperidolThe risk or severity of adverse effects can be increased when Haloperidol is combined with Cinchocaine.
HalothaneThe risk or severity of adverse effects can be increased when Cinchocaine is combined with Halothane.
HeroinThe risk or severity of adverse effects can be increased when Cinchocaine is combined with Heroin.
HexobarbitalThe risk or severity of adverse effects can be increased when Cinchocaine is combined with Hexobarbital.
HyaluronidaseThe risk or severity of adverse effects can be increased when Hyaluronidase is combined with Cinchocaine.
HydrocodoneThe risk or severity of adverse effects can be increased when Cinchocaine is combined with Hydrocodone.
HydromorphoneThe risk or severity of adverse effects can be increased when Hydromorphone is combined with Cinchocaine.
HydroxyzineHydroxyzine may increase the central nervous system depressant (CNS depressant) activities of Cinchocaine.
HydroxyzineThe risk or severity of adverse effects can be increased when Cinchocaine is combined with Hydroxyzine.
IloperidoneThe risk or severity of adverse effects can be increased when Cinchocaine is combined with Iloperidone.
ImipramineThe risk or severity of adverse effects can be increased when Cinchocaine is combined with Imipramine.
IndalpineThe risk or severity of adverse effects can be increased when Cinchocaine is combined with Indalpine.
IsofluraneThe risk or severity of adverse effects can be increased when Cinchocaine is combined with Isoflurane.
KetamineThe risk or severity of adverse effects can be increased when Cinchocaine is combined with Ketamine.
KetazolamThe risk or severity of adverse effects can be increased when Cinchocaine is combined with Ketazolam.
KetobemidoneThe risk or severity of adverse effects can be increased when Cinchocaine is combined with Ketobemidone.
LamotrigineThe risk or severity of adverse effects can be increased when Cinchocaine is combined with Lamotrigine.
LevetiracetamThe risk or severity of adverse effects can be increased when Cinchocaine is combined with Levetiracetam.
LevobupivacaineThe risk or severity of adverse effects can be increased when Cinchocaine is combined with Levobupivacaine.
LevocabastineThe risk or severity of adverse effects can be increased when Cinchocaine is combined with Levocabastine.
LevocetirizineThe risk or severity of adverse effects can be increased when Cinchocaine is combined with Levocetirizine.
LevodopaThe risk or severity of adverse effects can be increased when Cinchocaine is combined with Levodopa.
Levomethadyl AcetateThe risk or severity of adverse effects can be increased when Cinchocaine is combined with Levomethadyl Acetate.
LevomilnacipranThe risk or severity of adverse effects can be increased when Cinchocaine is combined with Levomilnacipran.
LevorphanolThe risk or severity of adverse effects can be increased when Cinchocaine is combined with Levorphanol.
LidocaineThe risk or severity of adverse effects can be increased when Lidocaine is combined with Cinchocaine.
LithiumThe risk or severity of adverse effects can be increased when Cinchocaine is combined with Lithium.
LofentanilThe risk or severity of adverse effects can be increased when Cinchocaine is combined with Lofentanil.
LoratadineThe risk or severity of adverse effects can be increased when Cinchocaine is combined with Loratadine.
LorazepamThe risk or severity of adverse effects can be increased when Lorazepam is combined with Cinchocaine.
LoxapineThe risk or severity of adverse effects can be increased when Loxapine is combined with Cinchocaine.
Lu AA21004The risk or severity of adverse effects can be increased when Cinchocaine is combined with Lu AA21004.
LurasidoneThe risk or severity of adverse effects can be increased when Cinchocaine is combined with Lurasidone.
Magnesium SulfateMagnesium Sulfate may increase the central nervous system depressant (CNS depressant) activities of Cinchocaine.
Magnesium SulfateThe risk or severity of adverse effects can be increased when Cinchocaine is combined with Magnesium Sulfate.
MaprotilineThe risk or severity of adverse effects can be increased when Cinchocaine is combined with Maprotiline.
MeclizineThe risk or severity of adverse effects can be increased when Cinchocaine is combined with Meclizine.
MedetomidineThe risk or severity of adverse effects can be increased when Cinchocaine is combined with Medetomidine.
MelatoninThe risk or severity of adverse effects can be increased when Cinchocaine is combined with Melatonin.
MelperoneThe risk or severity of adverse effects can be increased when Cinchocaine is combined with Melperone.
MepivacaineThe risk or severity of adverse effects can be increased when Cinchocaine is combined with Mepivacaine.
MeprobamateThe risk or severity of adverse effects can be increased when Meprobamate is combined with Cinchocaine.
MesoridazineThe risk or severity of adverse effects can be increased when Cinchocaine is combined with Mesoridazine.
MetaxaloneThe risk or severity of adverse effects can be increased when Cinchocaine is combined with Metaxalone.
MethadoneThe risk or severity of adverse effects can be increased when Methadone is combined with Cinchocaine.
Methadyl AcetateThe risk or severity of adverse effects can be increased when Cinchocaine is combined with Methadyl Acetate.
MethapyrileneThe risk or severity of adverse effects can be increased when Cinchocaine is combined with Methapyrilene.
MethaqualoneThe risk or severity of adverse effects can be increased when Cinchocaine is combined with Methaqualone.
MethocarbamolThe risk or severity of adverse effects can be increased when Cinchocaine is combined with Methocarbamol.
MethohexitalThe risk or severity of adverse effects can be increased when Methohexital is combined with Cinchocaine.
MethotrimeprazineThe risk or severity of adverse effects can be increased when Cinchocaine is combined with Methotrimeprazine.
MethoxyfluraneThe risk or severity of adverse effects can be increased when Cinchocaine is combined with Methoxyflurane.
MethsuximideThe risk or severity of adverse effects can be increased when Cinchocaine is combined with Methsuximide.
MethylphenobarbitalThe risk or severity of adverse effects can be increased when Cinchocaine is combined with Methylphenobarbital.
MetyrosineCinchocaine may increase the sedative activities of Metyrosine.
MidazolamThe risk or severity of adverse effects can be increased when Cinchocaine is combined with Midazolam.
MilnacipranThe risk or severity of adverse effects can be increased when Cinchocaine is combined with Milnacipran.
MinocyclineMinocycline may increase the central nervous system depressant (CNS depressant) activities of Cinchocaine.
MirtazapineCinchocaine may increase the central nervous system depressant (CNS depressant) activities of Mirtazapine.
MirtazapineThe risk or severity of adverse effects can be increased when Mirtazapine is combined with Cinchocaine.
MolindoneThe risk or severity of adverse effects can be increased when Cinchocaine is combined with Molindone.
MorphineThe risk or severity of adverse effects can be increased when Morphine is combined with Cinchocaine.
NabiloneNabilone may increase the central nervous system depressant (CNS depressant) activities of Cinchocaine.
NabiloneThe risk or severity of adverse effects can be increased when Cinchocaine is combined with Nabilone.
NalbuphineThe risk or severity of adverse effects can be increased when Cinchocaine is combined with Nalbuphine.
NitrazepamThe risk or severity of adverse effects can be increased when Cinchocaine is combined with Nitrazepam.
Nitrous oxideThe risk or severity of adverse effects can be increased when Cinchocaine is combined with Nitrous oxide.
NormethadoneThe risk or severity of adverse effects can be increased when Cinchocaine is combined with Normethadone.
NortriptylineThe risk or severity of adverse effects can be increased when Cinchocaine is combined with Nortriptyline.
OlanzapineThe risk or severity of adverse effects can be increased when Cinchocaine is combined with Olanzapine.
OlopatadineThe risk or severity of adverse effects can be increased when Cinchocaine is combined with Olopatadine.
OndansetronThe risk or severity of adverse effects can be increased when Cinchocaine is combined with Ondansetron.
OpiumThe risk or severity of adverse effects can be increased when Cinchocaine is combined with Opium.
OrphenadrineCinchocaine may increase the central nervous system depressant (CNS depressant) activities of Orphenadrine.
OrphenadrineThe risk or severity of adverse effects can be increased when Orphenadrine is combined with Cinchocaine.
OsanetantThe risk or severity of adverse effects can be increased when Cinchocaine is combined with Osanetant.
OxazepamThe risk or severity of adverse effects can be increased when Cinchocaine is combined with Oxazepam.
OxprenololThe risk or severity of adverse effects can be increased when Cinchocaine is combined with Oxprenolol.
OxybuprocaineThe risk or severity of adverse effects can be increased when Cinchocaine is combined with Oxybuprocaine.
OxycodoneThe risk or severity of adverse effects can be increased when Oxycodone is combined with Cinchocaine.
OxymorphoneThe risk or severity of adverse effects can be increased when Cinchocaine is combined with Oxymorphone.
PaliperidoneThe risk or severity of adverse effects can be increased when Cinchocaine is combined with Paliperidone.
ParaldehydeCinchocaine may increase the central nervous system depressant (CNS depressant) activities of Paraldehyde.
ParaldehydeThe risk or severity of adverse effects can be increased when Paraldehyde is combined with Cinchocaine.
ParoxetineThe risk or severity of adverse effects can be increased when Cinchocaine is combined with Paroxetine.
PentazocineThe risk or severity of adverse effects can be increased when Cinchocaine is combined with Pentazocine.
PentobarbitalThe risk or severity of adverse effects can be increased when Pentobarbital is combined with Cinchocaine.
PerampanelThe risk or severity of adverse effects can be increased when Cinchocaine is combined with Perampanel.
PerospironeThe risk or severity of adverse effects can be increased when Cinchocaine is combined with Perospirone.
PerphenazineThe risk or severity of adverse effects can be increased when Cinchocaine is combined with Perphenazine.
PethidineThe risk or severity of adverse effects can be increased when Pethidine is combined with Cinchocaine.
PhenobarbitalThe risk or severity of adverse effects can be increased when Cinchocaine is combined with Phenobarbital.
PhenoxyethanolThe risk or severity of adverse effects can be increased when Cinchocaine is combined with Phenoxyethanol.
PhenytoinThe risk or severity of adverse effects can be increased when Cinchocaine is combined with Phenytoin.
PimozideThe risk or severity of adverse effects can be increased when Cinchocaine is combined with Pimozide.
PipamperoneThe risk or severity of adverse effects can be increased when Cinchocaine is combined with Pipamperone.
PipotiazineThe risk or severity of adverse effects can be increased when Cinchocaine is combined with Pipotiazine.
PizotifenThe risk or severity of adverse effects can be increased when Cinchocaine is combined with Pizotifen.
PomalidomideThe risk or severity of adverse effects can be increased when Cinchocaine is combined with Pomalidomide.
PramipexoleCinchocaine may increase the sedative activities of Pramipexole.
PramocaineThe risk or severity of adverse effects can be increased when Cinchocaine is combined with Pramocaine.
PrazepamThe risk or severity of adverse effects can be increased when Cinchocaine is combined with Prazepam.
PregabalinThe risk or severity of adverse effects can be increased when Pregabalin is combined with Cinchocaine.
PrilocaineThe risk or severity of adverse effects can be increased when Cinchocaine is combined with Prilocaine.
PrimidoneThe risk or severity of adverse effects can be increased when Cinchocaine is combined with Primidone.
ProcaineThe risk or severity of adverse effects can be increased when Cinchocaine is combined with Procaine.
ProchlorperazineThe risk or severity of adverse effects can be increased when Prochlorperazine is combined with Cinchocaine.
PromazineThe risk or severity of adverse effects can be increased when Promazine is combined with Cinchocaine.
PromethazineThe risk or severity of adverse effects can be increased when Cinchocaine is combined with Promethazine.
ProparacaineThe risk or severity of adverse effects can be increased when Cinchocaine is combined with Proparacaine.
PropofolThe risk or severity of adverse effects can be increased when Cinchocaine is combined with Propofol.
PropoxycaineThe risk or severity of adverse effects can be increased when Cinchocaine is combined with Propoxycaine.
ProtriptylineThe risk or severity of adverse effects can be increased when Cinchocaine is combined with Protriptyline.
PSD502The risk or severity of adverse effects can be increased when Cinchocaine is combined with PSD502.
QuazepamThe risk or severity of adverse effects can be increased when Cinchocaine is combined with Quazepam.
QuetiapineThe risk or severity of adverse effects can be increased when Cinchocaine is combined with Quetiapine.
RamelteonThe risk or severity of adverse effects can be increased when Cinchocaine is combined with Ramelteon.
RemifentanilThe risk or severity of adverse effects can be increased when Cinchocaine is combined with Remifentanil.
RemoxiprideThe risk or severity of adverse effects can be increased when Remoxipride is combined with Cinchocaine.
ReserpineThe risk or severity of adverse effects can be increased when Reserpine is combined with Cinchocaine.
RisperidoneThe risk or severity of adverse effects can be increased when Cinchocaine is combined with Risperidone.
RomifidineThe risk or severity of adverse effects can be increased when Cinchocaine is combined with Romifidine.
RopiniroleCinchocaine may increase the sedative activities of Ropinirole.
RopivacaineThe risk or severity of adverse effects can be increased when Ropivacaine is combined with Cinchocaine.
RotigotineCinchocaine may increase the sedative activities of Rotigotine.
RufinamideThe risk or severity of adverse effects can be increased when Rufinamide is combined with Cinchocaine.
S-EthylisothioureaThe risk or severity of adverse effects can be increased when Cinchocaine is combined with S-Ethylisothiourea.
ScopolamineThe risk or severity of adverse effects can be increased when Cinchocaine is combined with Scopolamine.
SecobarbitalThe risk or severity of adverse effects can be increased when Secobarbital is combined with Cinchocaine.
SertindoleThe risk or severity of adverse effects can be increased when Cinchocaine is combined with Sertindole.
SertralineThe risk or severity of adverse effects can be increased when Cinchocaine is combined with Sertraline.
SevofluraneThe risk or severity of adverse effects can be increased when Cinchocaine is combined with Sevoflurane.
Sodium oxybateThe risk or severity of adverse effects can be increased when Cinchocaine is combined with Sodium oxybate.
StiripentolThe risk or severity of adverse effects can be increased when Cinchocaine is combined with Stiripentol.
SufentanilThe risk or severity of adverse effects can be increased when Cinchocaine is combined with Sufentanil.
SulpirideThe risk or severity of adverse effects can be increased when Sulpiride is combined with Cinchocaine.
SuvorexantThe risk or severity of adverse effects can be increased when Cinchocaine is combined with Suvorexant.
TapentadolThe risk or severity of adverse effects can be increased when Cinchocaine is combined with Tapentadol.
TasimelteonThe risk or severity of adverse effects can be increased when Cinchocaine is combined with Tasimelteon.
Technetium Tc-99m tilmanoceptCinchocaine may decrease effectiveness of Technetium Tc-99m tilmanocept as a diagnostic agent.
TemazepamThe risk or severity of adverse effects can be increased when Temazepam is combined with Cinchocaine.
TetrabenazineThe risk or severity of adverse effects can be increased when Cinchocaine is combined with Tetrabenazine.
TetracaineThe risk or severity of adverse effects can be increased when Cinchocaine is combined with Tetracaine.
TetrodotoxinThe risk or severity of adverse effects can be increased when Cinchocaine is combined with Tetrodotoxin.
ThalidomideCinchocaine may increase the central nervous system depressant (CNS depressant) activities of Thalidomide.
ThalidomideThe risk or severity of adverse effects can be increased when Thalidomide is combined with Cinchocaine.
ThiamylalThe risk or severity of adverse effects can be increased when Cinchocaine is combined with Thiamylal.
ThiopentalThe risk or severity of adverse effects can be increased when Cinchocaine is combined with Thiopental.
ThioridazineThe risk or severity of adverse effects can be increased when Cinchocaine is combined with Thioridazine.
ThiothixeneThe risk or severity of adverse effects can be increased when Cinchocaine is combined with Thiothixene.
TiagabineThe risk or severity of adverse effects can be increased when Cinchocaine is combined with Tiagabine.
TiletamineThe risk or severity of adverse effects can be increased when Cinchocaine is combined with Tiletamine.
TizanidineThe risk or severity of adverse effects can be increased when Cinchocaine is combined with Tizanidine.
TolcaponeThe risk or severity of adverse effects can be increased when Cinchocaine is combined with Tolcapone.
TopiramateThe risk or severity of adverse effects can be increased when Cinchocaine is combined with Topiramate.
TramadolThe risk or severity of adverse effects can be increased when Tramadol is combined with Cinchocaine.
Trans-2-PhenylcyclopropylamineThe risk or severity of adverse effects can be increased when Cinchocaine is combined with Trans-2-Phenylcyclopropylamine.
TranylcypromineThe risk or severity of adverse effects can be increased when Cinchocaine is combined with Tranylcypromine.
TrazodoneThe risk or severity of adverse effects can be increased when Cinchocaine is combined with Trazodone.
TriazolamThe risk or severity of adverse effects can be increased when Cinchocaine is combined with Triazolam.
TrifluoperazineThe risk or severity of adverse effects can be increased when Cinchocaine is combined with Trifluoperazine.
TriflupromazineThe risk or severity of adverse effects can be increased when Triflupromazine is combined with Cinchocaine.
TrimipramineThe risk or severity of adverse effects can be increased when Cinchocaine is combined with Trimipramine.
TriprolidineThe risk or severity of adverse effects can be increased when Cinchocaine is combined with Triprolidine.
Valproic AcidThe risk or severity of adverse effects can be increased when Valproic Acid is combined with Cinchocaine.
VigabatrinThe risk or severity of adverse effects can be increased when Cinchocaine is combined with Vigabatrin.
VilazodoneThe risk or severity of adverse effects can be increased when Cinchocaine is combined with Vilazodone.
VortioxetineThe risk or severity of adverse effects can be increased when Cinchocaine is combined with Vortioxetine.
XylazineThe risk or severity of adverse effects can be increased when Cinchocaine is combined with Xylazine.
ZaleplonThe risk or severity of adverse effects can be increased when Cinchocaine is combined with Zaleplon.
ZiconotideThe risk or severity of adverse effects can be increased when Cinchocaine is combined with Ziconotide.
ZimelidineThe risk or severity of adverse effects can be increased when Cinchocaine is combined with Zimelidine.
ZiprasidoneThe risk or severity of adverse effects can be increased when Ziprasidone is combined with Cinchocaine.
ZolazepamThe risk or severity of adverse effects can be increased when Cinchocaine is combined with Zolazepam.
ZolpidemThe risk or severity of adverse effects can be increased when Zolpidem is combined with Cinchocaine.
ZonisamideThe risk or severity of adverse effects can be increased when Cinchocaine is combined with Zonisamide.
ZopicloneThe risk or severity of adverse effects can be increased when Cinchocaine is combined with Zopiclone.
ZotepineThe risk or severity of adverse effects can be increased when Cinchocaine is combined with Zotepine.
ZuclopenthixolThe risk or severity of adverse effects can be increased when Cinchocaine is combined with Zuclopenthixol.
Food InteractionsNot Available

Targets

Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
inhibitor
General Function:
Voltage-gated sodium channel activity involved in sa node cell action potential
Specific Function:
This protein mediates the voltage-dependent sodium ion permeability of excitable membranes. Assuming opened or closed conformations in response to the voltage difference across the membrane, the protein forms a sodium-selective channel through which Na(+) ions may pass in accordance with their electrochemical gradient. It is a tetrodotoxin-resistant Na(+) channel isoform. This channel is respon...
Gene Name:
SCN5A
Uniprot ID:
Q14524
Molecular Weight:
226937.475 Da
References
  1. Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. [PubMed:17139284 ]
  2. Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. [PubMed:17016423 ]
  3. Oka M, Itoh Y, Fujita T: Halothane attenuates the cerebroprotective action of several Na+ and Ca2+ channel blockers via reversal of their ion channel blockade. Eur J Pharmacol. 2002 Oct 4;452(2):175-81. [PubMed:12354567 ]
  4. Louro SR, Anteneodo C, Wajnberg E: Carboxyl groups at the membrane interface as molecular targets for local anesthetics. Biophys Chem. 1998 Aug 4;74(1):35-43. [PubMed:9742684 ]
  5. Ryan SE, Demers CN, Chew JP, Baenziger JE: Structural effects of neutral and anionic lipids on the nicotinic acetylcholine receptor. An infrared difference spectroscopy study. J Biol Chem. 1996 Oct 4;271(40):24590-7. [PubMed:8798723 ]
  6. Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. [PubMed:11752352 ]
Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
inhibitor
General Function:
Voltage-gated sodium channel activity
Specific Function:
Tetrodotoxin-resistant channel that mediates the voltage-dependent sodium ion permeability of excitable membranes. Assuming opened or closed conformations in response to the voltage difference across the membrane, the protein forms a sodium-selective channel through which sodium ions may pass in accordance with their electrochemical gradient. Plays a role in neuropathic pain mechanisms.
Gene Name:
SCN10A
Uniprot ID:
Q9Y5Y9
Molecular Weight:
220623.605 Da
References
  1. Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. [PubMed:17139284 ]
  2. Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. [PubMed:17016423 ]
  3. Louro SR, Anteneodo C, Wajnberg E: Carboxyl groups at the membrane interface as molecular targets for local anesthetics. Biophys Chem. 1998 Aug 4;74(1):35-43. [PubMed:9742684 ]
  4. Ryan SE, Demers CN, Chew JP, Baenziger JE: Structural effects of neutral and anionic lipids on the nicotinic acetylcholine receptor. An infrared difference spectroscopy study. J Biol Chem. 1996 Oct 4;271(40):24590-7. [PubMed:8798723 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inhibitor
General Function:
Titin binding
Specific Function:
Calmodulin mediates the control of a large number of enzymes, ion channels, aquaporins and other proteins by Ca(2+). Among the enzymes to be stimulated by the calmodulin-Ca(2+) complex are a number of protein kinases and phosphatases. Together with CCP110 and centrin, is involved in a genetic pathway that regulates the centrosome cycle and progression through cytokinesis.
Gene Name:
CALM1
Uniprot ID:
P62158
Molecular Weight:
16837.47 Da
References
  1. Muto Y, Kudo S, Nozawa Y: Effects of local anesthetics on calmodulin-dependent guanylate cyclase in the plasma membrane of Tetrahymena pyriformis. Biochem Pharmacol. 1983 Dec 1;32(23):3559-63. [PubMed:6140014 ]
  2. Volpi M, Sha'afi RI, Epstein PM, Andrenyak DM, Feinstein MB: Local anesthetics, mepacrine, and propranolol are antagonists of calmodulin. Proc Natl Acad Sci U S A. 1981 Feb;78(2):795-9. [PubMed:6262771 ]
  3. Liu SH, Fu WM, Lin-Shiau SY: Studies on the inhibition by chlorpromazine of myotonia induced by ion channel modulators in mouse skeletal muscle. Eur J Pharmacol. 1993 Jan 26;231(1):23-30. [PubMed:7680317 ]
  4. Sambandam T, Gunasekaran M: Purification and properties of calmodulin from Phymatotrichum omnivorum. Microbios. 1993;73(294):61-74. [PubMed:8382768 ]

Enzymes

Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inhibitor
General Function:
Identical protein binding
Specific Function:
Esterase with broad substrate specificity. Contributes to the inactivation of the neurotransmitter acetylcholine. Can degrade neurotoxic organophosphate esters.
Gene Name:
BCHE
Uniprot ID:
P06276
Molecular Weight:
68417.575 Da
References
  1. Elamin B: Dibucaine inhibition of serum cholinesterase. J Biochem Mol Biol. 2003 Mar 31;36(2):149-53. [PubMed:12689511 ]
Comments
comments powered by Disqus
Drug created on June 13, 2005 07:24 / Updated on August 17, 2016 12:23